1 / 46

HEART FAILURE

HEART FAILURE . Congestive heart failure (CHF) is the clinical state of systemic and pulmonary congestion resulting from inability of the heart to pump as much blood as required for the adequate metabolism of the body.

kasi
Download Presentation

HEART FAILURE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HEART FAILURE

  2. Congestive heart failure (CHF) istheclinical state of systemic and pulmonary congestion resulting from inability of the heart to pump as much blood as required for the adequate metabolism of the body. Clinical picture of CHF results from a combination of “low output” and compensatory responses to increase it

  3. PATHOPHYSIOLOGY Tissue demands for cardiac outputactivates: • Renin-aldosteroneangiotensin system • Sympathetic nervous system • Cytokine-induced inflammation • “Signaling” cascades that trigger cachexia.

  4. Longstanding increases in myocardial work and myocardial oxygen consumption (MVO2) ultimately worsen HF symptoms and lead to a chronic phase that involves cardiac remodeling

  5. CARDIAC REMODELING Maladaptive cardiac hypertrophy Expansion of the myofibrillar components of individual myocytes (new cells rarely form) An increase in the myocyte/capillary ratio Activation and proliferation of abundant nonmyocytecardiac cells, some of which produce cardiac scarring Produce a poorly contractile and less compliant heart

  6. CLINICAL MANIFESTATIONS IN INFANTS WITH HF • Variety of age dependent clinical presentations • In neonates, the earliest clinical manifestations may be subtle

  7. CLINICAL MANIFESTATIONS IN INFANTS WITH CHF • Feeding difficulties • Rapid respirations • Tachycardia • Cardiacenlargement • Gallop rhythm (S3) • Hepatomegaly • Pulmonary rales • Peripheral edema • Easy fatigability. • Sweating • Irritability • failure to thrive.

  8. Feeding difficulties & increased fatigability Important clue in detecting CHF in infants • Often it is noticed by mother • Interrupted feeding (suck- rest -suck cycles) • Infant pauses frequently to rest during feedings • Inability to finish the feed, taking longer to finish each feed (> 30 minutes) • Forehead sweating during feeds –due to activation of sympathetic nervous system –a very useful sign • Increasing symptoms during and after feedings

  9. Rapid respirations • Tachypnea > 60/min in 0-2mth >50/mt in 2mth to 1yr >40/mt 1-5 yr in calm child • Grunting (a form of positive end-expiratory pressure) • Fever especially with a pulmonary infection may produce rapid respirations.

  10. Tachycardia • Rate is difficult to evaluate in a crying or moving child • Tachycardia in the absence of fever or crying when accompanied by rapid respirations and hepatomegaly is indicative of HF • Persistently raised heart rate > 160 bpm in infants • > 100 bpm in older children. • Consider SVT if heart rate > 220 bpm in infants and > 180 bpm in older children.

  11. Cardiomegaly • Consistent sign of impaired cardiac function, secondary to ventricular dilatation and/or hypertrophy. • May be absent in early stages, especially with myocarditis, arrhythmias, restrictive disorders and pulmonary venous obstruction(obstructed TAPVC) • Apex 4th space 1cm outside MCL in newborn

  12. Hepatomegaly • Lower edge of the liver is palpable 1 to 2 cms below right costal margin normally in infancy • In the presence of respiratory infection increased expansion of the lungs displace liver caudally • Usually in such circumstances the spleen is palpable • Hepatomegaly is a sign of CHF • Decrease in size is an excellent criterion of response to therapy

  13. Pulmonary rales • Of not much use in detecting CHF in infants • Rales may be heard at both lung bases • When present are difficult to differentiate from those due to the pulmonary infection which frequently accompanies failure

  14. Peripheral edema • Edema is a very late sign of failure in infants and children • Presacral and posterior chest wall edema in young infants • It indicates a very severe degree of failure. • Daily weight monitoring is useful in neonates -- rapid increase > 30 gm /day may be a clue to CCF and is useful in monitoring response to treatment.

  15. Cold extremity, low blood pressure, skin mottling are signs of impending shock Pulsusalternans (alternate strong and weak contractions of a failing myocardium),or pulsusparadoxus (decrease in pulse volume and blood pressure with inspiration) are frequently observed in infants with severe CHF

  16. CLASSIFICATION • NYHA Heart Failure Classification is not applicable • Ross Heart Failure Classification was developed for global assessment of heart failure severity in infants • Modified to apply to all pediatric ages • Modified Ross Classification incorporates Feeding difficulties Growth problems Symptoms of exercise intolerance

  17. MODIFIED ROSS HEART FAILURE CLASSIFICATION FOR CHILDREN Class I • Asymptomatic Class II • Mild tachypnea or diaphoresis with feeding in infants • Dyspnea on exertion in older children Class III • Marked tachypnea or diaphoresis with feeding in infants • Marked dyspnea on exertion • Prolonged feeding times with growth failure Class IV • Symptoms such as tachypnea, retractions, grunting, or diaphoresis at rest

  18. CAUSES OF HF IN CHILDREN CARDIAC Congenital structural malformations ● Excessive Preload ● Excessive Afterload ● Complex congenital heart disease No structural anomalies ● Cardiomyopathy ● Myocarditis ● Myocardial infarction ● Acquired valve disorders ● Hypertension ● Kawasaki syndrome ● Arrhythmia (bradycardia or tachycardia) NONCARDIAC ● Anemia ● Sepsis ● Hypoglycemia ● Diabetic ketoacidosis ● Hypothyroidism ● Other endocrinopathies ● Arteriovenous fistula ● Renal failure ● Muscular dystrophies

  19. CONGENITAL STRUCTURAL MALFORMATIONS

  20. VOLUME OVERLOAD (EXCESSIVE PRELOAD) • Left-to-right shunting VSD PDA AVSD (Atrioventricular septaldefect) ASD(rare) Total/Partial Anomalous Pulmonary Venous Connection • AV or semilunar valve insufficiency MR (Mitral regurgitation) after repair of AVSD PR after repair of TOF( Tetralogy of Fallot) Severe TR in Ebstein anomaly

  21. PRESSURE OVERLOAD (EXCESSIVE AFTERLOAD) Left sided obstruction Congenital AS Aortic coarctation Lethal arrhythmias - severe afterload stress Right-sided obstruction Severe PS

  22. CHF (congestive heartfailure) WITHOUT CARDIAC MALFORMATIONS PRIMARY CARDIAC • Cardiomyopathy • Myocarditis • Cardiac ischemia • Acquired valve disorders • Hypertension • Kawasaki syndrome • Arrhythmia (bradycardiaor tachycardia) NONCARDIAC • Anemia • Sepsis • Hypoglycemia • Diabetic ketoacidosis • Hypothyroidism • Other endocrinopathies • Arteriovenous fistula • Renal failure • Muscular dystrophies

  23. DISORDERS OF CONTRACTILITY • Cardiomyopathy is a genetically triggered or acquired disease • Occurs in approximately 1.13 in 100,000 children • Characterized by enlarged ventricular chambers and impaired systolic and diastolic function • Usually idiopathic Infection (myocarditis viral-enterovirus) Operative injury Consequence of degenerative or metabolic diseases Muscular dystrophies Mitochondriopathy, Hyperthyroidism carnitine deficiency

  24. Restrictive cardiomyopathy Idiopathic Infiltrative or storage diseases hemochromatosis Pompe disease Hypertrophic cardiomyopathy • Idiopathic hypertrophic subaortic stenosis, rarely associated with pediatric HF.

  25. TACHYCARDIA • Diastolic filling time shortens to and cardiac output is decreased. • Most common childhood tachyarrhythmia is SVT • Often presents in the first few months of life • Rarely cause heart failure • Occasionally Persistent Junctional Reciprocating Tachycardia (PJRT) ,ectopic atrial tachycardia and VT

  26. CHRONIC BRADYCARDIAS • LV enlarges to accommodate larger stroke volumes • Chamber dilation reaches a limit that cannot be compensated without increase in heart rate • Febrile states are particularly stressful • Congenital CHB may be well-tolerated in utero • Children with congenital CHB who are pacemaker dependent are at risk of subsequent pacemaker-mediated cardiomyopathy

  27. CARDIAC ISCHEMIA Relatively rare in children ALCAPA (Anomalous Left Coronary Artery from the Pulmonary Artery Palliative surgery that requires reconstruction of or near the coronary arteries

  28. LABORATORY STUDIES • PULSE OXIMETRY • ECG • ABG (Arterial BloodGas)

  29. CXR • Size of the heart is difficult to determine radiologically, particularly if there is a superimposed thymic shadow. • Enlarged cardiac shadow unassociated with signs of CHF- suspect that shadow noncardiac • Absence of cardiomegaly in a good inspiratory film (with diaphragm near the 10th rib posteriorly) practically excludes CHF except due to a cause like obstructed total anomalous pulmonary venous connection (TAPVC)

  30. CT Ratio method, > 60% Massive cardiomegaly RA dilation Pulm plethora LV Dialatation

  31. ECHOCARDIOGRAPHY • Doppler myocardial performance index • Causes of HF such as structural heart disease • Ventricular dysfunction (both systolic and diastolic) • Chamber dimensions • Effusions (both pericardial and pleural)

  32. PRINCIPLES OF MANAGINGHEART FAILURE • Recognition and treatment of underlying systemic disease • Timely Surgical Repair of Structural Anomalies Afterload Reduction • ACE ( Angiotensinconvertingenzyme )inhibitors • ARB (angiotensin receptor blockers • Milrinone Type 4 phosphodiesterase inhibitors • Nitrates • Recombinant BNP =brainnatriuretic peptide

  33. Preload Reduction • Diuretics • BNP Sympathetic Inhibition • Beta blockers • Recombinant BNP • Digoxin Cardiac Remodeling Prevention • Mineralocorticoid inhibitors Inotropy • Digoxin

  34. MEDICAL THERAPY • Medical management aims to maximize cardiac output and tissue perfusion • Goals are accomplished by reducing afterloadstress and preload • Treatments that “rest” the heart such as vasodilators are preferred to inotropic agents that increase MVO2

  35. GENERAL MEASURES • Bed rest and limit activities • Nurse propped up or in sitting position • Control fever • Expressed breast milk for small infants • Fluid restriction in volume overloaded • Optimal sedation • Correction of anemia ,acidosis, hypoglycemia and hypocalcaemia if present • Oxygen –caution in LT-RT shunt as pulmonary vasodilation my increase shunt • CPAP (Continuouspositiveairwaypressure) or mechanical ventilation as necessary

  36. CONGENITAL HEART DISEASE: VOLUME OVERLOAD • General therapeutic approach is to minimize symptoms and optimize growth until a definitive procedure can be performed. • Mainstays of medical therapy are digitalis and diuretics.

  37. DIGITALIS • Digitalis considered as essential component • Evidence for efficacy is less in volume-overload lesions with normal function where the mild inotropic effect of digitalis is unnecessary • Sympatholytic properties may modulate pathological neurohormonal activation

  38. LOOP DIURETICS • Furosemide improved clinical symptoms on a background of digitalis administration • Decrease pulmonary congestion and thus decrease the work of breathing • It is one of the least toxic diuretics in pediatrics • Associated with sensorineural hearing loss after long-term administration in neonatal respiratory distress • Deafness related to speed of infusion • Torasemide is also safe and effective in this group

  39. ACE (angiotensin-converting-enzymeinhibitors ) • Improved growth was seen in some children with CHF • Captopril and enalapril • Concerning incidence of renal failure particularly in premature and very young infants. • No efficacy data on ARBs in children with heart failure

  40. CARDIOMYOPATHIES • Torasemide, a newer loop diuretic with potassium-sparing properties, significantly improved New York University Pediatric Heart Failure Index, decreased BNP levels, and improved fractional shortening

  41. Paediatriccarvedilol doses 1mg/kg/day for adolescents 2mg/kg/day for children aged 2 to 11 years 3mg/kg/day for infants (aged 28 days to 23 months) • Carvedilol used in many of the studies have been lower than these recommendations

  42. Treatment of primary diastolic heart failure in children with hypertrophic or restrictive cardiomyopathy are limited to the judicious use of diuretics to decrease the degree of pulmonary congestion.

  43. Inotropes in acute cardiac failure • Routine use of in children cannot be recommended • Used in treatment of exacerbating conditions and as a bridging therapy pending transplantation • Dopamine as it possesses both the cardiac and renal effects is more useful

  44. NUTRITION AND EXERCISE IN PEDIATRIC HEART FAILURE • Important as medical therapy, particularly in infants • Increase the caloric density of feeds as soon as a diagnosis • Sodium restriction is not recommended in infants and young children. • Sodium restriction can result in impaired body and brain growth

  45. Pacemaker and implantable defibrillator therapy • Biventricular pacing • Ventricular assist devices • Heart transplantation

More Related